Cytovance Biologics, Inc., a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca Ltd., a research and development organization with proprietary yeast expression technology for recombinant protein manufacture, have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing. The alliance aims to accelerate the development of high-performance yeast strains and to improve the efficiency of biologics...